-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia Therapeutics Presents Phase I Data Evaluating Concurrent Paxalisib And Radiation Therapy In Patients With Solid Tumor Brain Metastases Or Leptomeningeal Metastases Harboring PI3K Pathway Mutations At American Society For Radiation Oncology 66th Annual Meeting

Benzinga·10/02/2024 12:48:29
Listen to the news

Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR)

Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably to historical response rates for whole brain radiation therapy alone